Navigation Links
Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection
Date:8/5/2009

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S. market for these two products approximated $25 million in 2008. Sagent will begin marketing and shipping both products immediately.

"We are very pleased to begin expanding our product line to include vital oncology products," said Jeffrey M. Yordon, chief executive officer, founder and chairman of the board of Sagent. "Our epirubicin and fludarabine products are each latex and preservative free, and bear Sagent's hallmark packaging, designed to help healthcare providers quickly and accurately identify the right product and dose."

Fludarabine for injection, USP will be offered in 50 mg single-use vials. Epirubicin hydrochloride injection will be offered in 50 mg per 25 mL and 200 mg per 100 mL single-dose vials.

About Fludarabine Phosphate for Injection, USP

Fludarabine phosphate for injection, USP (generic equivalent to Fludara(R), distributed by Bayer HealthCare Pharmaceuticals) is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of the product in previously untreated or non-refractory patients with CLL have not been established.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About Epirubicin Hydrochloride Injection

Epirubicin hydrochloride injection (generic equivalent to Ellence(R)
'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
3. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
4. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
5. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
6. Sagent Pharmaceuticals Announces Extension of Series A Financing
7. Sagent Pharmaceuticals Enters Into a $15 Million Revolving Credit Facility
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email: